Summary
At 5 years, patients in the MANTRA-PAF trial treated with radiofrequency ablation had less atrial fibrillation burden and episodes of symptomatic atrial fibrillation compared with antiarrhythmic drug. However, there was no significant difference in quality of life measures.
- MANTRA-PAF
- atrial fibrillation
- antiarrhythmic drug
- radiofrequency ablation
- catheter ablation
- interventional techniques & devices
- arrhythmias
- cardiology & cardiovascular medicine clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.